Morgan Stanley lowered its target price for Hepalink (09989) to HK$14.3 from HK$15.1 and maintained its "overweight" rating.
The research house said it cuts its EPS estimates by 8% for 2021, 6% for 2022, and 4% in 2023, and also reduce its forecasts over 2024-2030, following 1H21 earnings.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情